Synaptogenix Inc (SNPX)

[Cyosol]

Neurotrope won't have any competition until 2026, considering how US patents generally last for 20 years and Dr. Alkons patents for PKC activators were filed around 2006.

http://google.com/patents/WO2007016202A1

The confirmatory trial will start before June, and let's say it will take twice as long as the previous one, which measured patients for 15 weeks. If the trial takes 30 weeks and starts on the 1st of June, it should be completed around late December 2018/early January 2019.

Now let's say they need a month or two to analyze the data and announce their findings. This brings us to a press release around February/March 2019.

Even if it takes the company all of 2019 to find a distribution partner and get FDA approval, they will still have a guaranteed 6 year monopoly on treating AD patients from 2020 to 2026.

Bryostatin being an IV drug is also not a problem, considering how all other alternatives basically consist out of either slightly delaying the disease (if at all) or letting the disease slowly kill you.

With 5 million people suffering from AD in the US alone, Neurotrope will have access to millions of potential customers they can charge any price they want for an entire 6 years.

Now let's say they'll charge $500 a month (I would gladly pay $500 a month if it meant keeping myself alive and my memories intact).

$500/month x 5 million patients x 12 months = Yearly revenues of at least $30 billion.

Even if they only reach a million patients and charge $300 a month for the drug, that's still $3.6 billion in yearly revenues.